HAS-BLED Calculator

Q: What is the HAS-BLED score and what does it assess?

The HAS-BLED score is a validated clinical prediction tool used to estimate the risk of major bleeding in patients with atrial fibrillation who are being considered for or are currently on anticoagulation therapy. The acronym stands for Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly, and Drugs/alcohol. Each component scores 1 point, with the maximum poss

Q: Should anticoagulation be withheld if the HAS-BLED score is high?

A high HAS-BLED score (3 or above) should NOT automatically lead to withholding anticoagulation in patients with atrial fibrillation. This is a critical and common misconception. The score was designed to identify patients at increased bleeding risk so that modifiable risk factors can be addressed, not to serve as a contraindication to anticoagulation. In most patients with atrial fibrillation and

Q: How does HAS-BLED compare to other bleeding risk scores?

Several bleeding risk scores exist for atrial fibrillation patients, but HAS-BLED has the most extensive validation and widest guideline endorsement. The ATRIA score uses five variables (anemia, renal disease, age, prior bleeding, hypertension) and categorizes risk as low, intermediate, or high. The ORBIT score uses five factors (older age, reduced hemoglobin/Hct, bleeding history, renal insuffici

Q: How is labile INR defined and measured in the HAS-BLED score?

Labile INR in the HAS-BLED score refers to unstable or fluctuating International Normalized Ratio values in patients taking vitamin K antagonists (warfarin). It is specifically defined as time in therapeutic range (TTR) less than 60%, meaning the patient spends less than 60% of their monitored time within the target INR range (typically 2.0-3.0 for atrial fibrillation). TTR can be calculated using

Q: What counts as abnormal renal function in HAS-BLED?

Abnormal renal function in the HAS-BLED score is defined as the presence of chronic dialysis, renal transplant, or serum creatinine of 2.26 mg/dL (200 micromol/L) or higher. This represents significant renal impairment that independently increases bleeding risk through multiple mechanisms. Impaired renal function affects platelet function and aggregation, prolongs bleeding time through uremic plat

Q: What is the clinical significance of prior bleeding history in HAS-BLED?

Prior bleeding history is one of the most important predictors of future bleeding risk and scores 1 point in HAS-BLED. It specifically refers to any previous major bleeding episode, defined as bleeding requiring hospitalization, causing a hemoglobin drop of 2 g/dL or more, or requiring blood transfusion, or bleeding in a critical site such as intracranial hemorrhage. Patients with prior bleeding h

Estimate your hasbledcalculator with our free cardiovascular system calculator. See reference ranges, risk factors, and next-step guidance.

Share this calculator

X Facebook LinkedIn

Formula

HAS-BLED = H + A + S + B + L + E + D (each factor scores 0 or 1, max 9)

H = Hypertension (SBP > 160), A = Abnormal renal/liver function (1 point each), S = Stroke history, B = Bleeding history, L = Labile INR (TTR < 60%), E = Elderly (> 65), D = Drugs/alcohol (1 point each). Score of 3 or above indicates high bleeding risk.

Worked Examples

Example 1: High Bleeding Risk Assessment

Problem: A 70-year-old patient on warfarin for atrial fibrillation has uncontrolled hypertension (SBP 170), creatinine 2.5 mg/dL, prior GI bleed, TTR 50%, and takes aspirin. Calculate HAS-BLED.

Solution: H - Hypertension (SBP > 160): 1 point\nA - Abnormal renal function (Cr > 2.26): 1 point\nS - Stroke: 0 points\nB - Bleeding history (prior GI bleed): 1 point\nL - Labile INR (TTR 50% < 60%): 1 point\nE - Elderly (age 70 > 65): 1 point\nD - Drugs (aspirin): 1 point\nTotal HAS-BLED = 6

Result: HAS-BLED Score: 6 | Risk: High | Annual bleeding risk: ~12.5% | Address modifiable factors urgently

Example 2: Low Bleeding Risk Patient

Problem: A 58-year-old patient with atrial fibrillation, no hypertension, normal renal/liver function, no prior strokes or bleeding, stable INR, no NSAIDs/antiplatelets, moderate alcohol use.

Solution: H - Hypertension: 0 points\nA - Abnormal function: 0 points\nS - Stroke: 0 points\nB - Bleeding: 0 points\nL - Labile INR: 0 points\nE - Elderly (58 < 65): 0 points\nD - Drugs: 0, Alcohol (moderate): 0 points\nTotal HAS-BLED = 0

Result: HAS-BLED Score: 0 | Risk: Low | Annual bleeding risk: ~1.1% | Safe to initiate anticoagulation

Frequently Asked Questions

What is the HAS-BLED score and what does it assess?

The HAS-BLED score is a validated clinical prediction tool used to estimate the risk of major bleeding in patients with atrial fibrillation who are being considered for or are currently on anticoagulation therapy. The acronym stands for Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly, and Drugs/alcohol. Each component scores 1 point, with the maximum possible score being 9 points. A score of 3 or higher indicates high bleeding risk, though this should not automatically preclude anticoagulation but rather prompt careful consideration of modifiable risk factors. The score was developed by Pisters and colleagues and has been endorsed by European and international cardiology guidelines.

Should anticoagulation be withheld if the HAS-BLED score is high?

A high HAS-BLED score (3 or above) should NOT automatically lead to withholding anticoagulation in patients with atrial fibrillation. This is a critical and common misconception. The score was designed to identify patients at increased bleeding risk so that modifiable risk factors can be addressed, not to serve as a contraindication to anticoagulation. In most patients with atrial fibrillation and a CHA2DS2-VASc score indicating stroke risk, the net clinical benefit of anticoagulation outweighs the bleeding risk even when HAS-BLED is elevated. The appropriate response to a high HAS-BLED score is to optimize modifiable factors (blood pressure control, INR stability, medication review, alcohol reduction) and ensure more frequent follow-up monitoring.

How does HAS-BLED compare to other bleeding risk scores?

Several bleeding risk scores exist for atrial fibrillation patients, but HAS-BLED has the most extensive validation and widest guideline endorsement. The ATRIA score uses five variables (anemia, renal disease, age, prior bleeding, hypertension) and categorizes risk as low, intermediate, or high. The ORBIT score uses five factors (older age, reduced hemoglobin/Hct, bleeding history, renal insufficiency, antiplatelet treatment). The HEMORR2HAGES score uses 11 variables, making it more complex to calculate. Comparative studies have shown that HAS-BLED generally has comparable or superior predictive performance (c-statistic approximately 0.60-0.65) and is significantly easier to calculate at the bedside. The ESC atrial fibrillation guidelines specifically recommend HAS-BLED for bleeding risk assessment.

How is labile INR defined and measured in the HAS-BLED score?

Labile INR in the HAS-BLED score refers to unstable or fluctuating International Normalized Ratio values in patients taking vitamin K antagonists (warfarin). It is specifically defined as time in therapeutic range (TTR) less than 60%, meaning the patient spends less than 60% of their monitored time within the target INR range (typically 2.0-3.0 for atrial fibrillation). TTR can be calculated using the Rosendaal method, which uses linear interpolation between consecutive INR measurements, or the simpler fraction-of-INR-in-range method. Labile INR increases both bleeding and thromboembolic risk. Patients with consistently labile INR should be evaluated for factors contributing to instability (dietary inconsistency, drug interactions, adherence issues) and may be better candidates for direct oral anticoagulants (DOACs), which do not require INR monitoring.

What counts as abnormal renal function in HAS-BLED?

Abnormal renal function in the HAS-BLED score is defined as the presence of chronic dialysis, renal transplant, or serum creatinine of 2.26 mg/dL (200 micromol/L) or higher. This represents significant renal impairment that independently increases bleeding risk through multiple mechanisms. Impaired renal function affects platelet function and aggregation, prolongs bleeding time through uremic platelet dysfunction, alters the metabolism and clearance of anticoagulant medications, and is associated with vascular fragility and increased risk of gastrointestinal bleeding. Patients with chronic kidney disease also frequently have anemia, which further compounds bleeding risk. When prescribing anticoagulants to patients with renal impairment, dose adjustments are critical, particularly for renally-cleared DOACs like dabigatran and edoxaban.

What is the clinical significance of prior bleeding history in HAS-BLED?

Prior bleeding history is one of the most important predictors of future bleeding risk and scores 1 point in HAS-BLED. It specifically refers to any previous major bleeding episode, defined as bleeding requiring hospitalization, causing a hemoglobin drop of 2 g/dL or more, or requiring blood transfusion, or bleeding in a critical site such as intracranial hemorrhage. Patients with prior bleeding have approximately 2-3 times the risk of recurrent bleeding on anticoagulation compared to those without bleeding history. However, this does not mean anticoagulation should be avoided. Rather, clinicians should investigate and treat the source of prior bleeding (such as gastric ulcers or colon polyps), consider using DOACs which may have lower GI bleeding rates for certain agents, and implement closer monitoring strategies.

References

Reviewed by Rahul Singh, Health & Wellness Specialist · Editorial policy